Genetic Technologies (ASX: GTG; NASDAQ: GENE) has now executed a Settlement and License Agreement with Reprogenetics, U.S.
Genetic filed suit against Reprogenetics under its patent assertion program in late 2012.
With the execution of this agreement, Genetic has authorised the dismissal of legal action against Reprogenetics.
The commercial terms of the agreement are covered by formal confidentiality provisions and cannot be disclosed.
Genetic Technologies is a diagnostics company commercialising genetic testing, cancer diagnosis, non-coding DNA and product patenting throughout licensing.
Genetic's US subsidiary Phenogen’s lead product, BREVAGen™, is a first in class, clinically validated risk assessment test for non-familial breast cancer.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.